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Edited by Robert BaroukiAbstract PEG10 is an imprinted gene which is up-regulated in
hepatocelluar carcinoma (HCC). However, the mechanism of
PEG10 regulation remains to be elucidated. In this work the tran-
scription factors E2F-1 and -4 were demonstrated to bind directly
to the promoter of PEG10 and thereby regulate its expression.
The expression proﬁle of HCC tissues also suggested E2Fs were
involved in PEG10 regulation. Further functional analysis showed
that PEG10 was involved in the repression of apoptosis induced by
serum deprivation and chemotherapeutic drugs. These ﬁndings
link cancer genetics and epigenetics by showing that E2F acts di-
rectly upstream of an anti-apoptosis imprinted gene, PEG10.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The PEG10 gene was identiﬁed based on its location in an im-
printed domain on human chromosome 7q21 and characterized
as paternally expressed/maternally silenced [1]. The PEG10
mRNA encodes two protein isoforms (RF1 and RF2) via trans-
lational frameshifting [2]. Overexpression of PEG10 in HCC
has been reported by several groups, indicating this gene has
growth-promoting activity [3–6]. However it may also be in-
volved in hepatocarcinogenesis by interacting with SIAH1, a
mediator of apoptosis [7]. A variety of experiments showed that
the expression of PEG10 can be regulated by androgen and it is
a target of c-MYC in cancer cells [8,9]. However, the regulated
mechanism of PEG10 is not elucidated.
E2F consists of a transcriptional factor family including six
distinct E2F members and at least two heterodimer partners,
DP1 and DP2 [10]. E2F family members regulate many genes
through their interaction with other cellular proteins. Included
among these so-called nuclear pocket proteins are Rb family
members, RB1, p107, and p130. Interaction between pocket
protein and E2F normally diminishes E2Fs trans-activating
capacity and inhibits target genes [11]. Although the pathway
to cell cycle progression seems straightforward with a number
of growth-promoting E2F target genes having been described,
the pathways to apoptosis are less well deﬁned and more
complex [10,12].*Corresponding author. Fax: +86 21 54921342.
E-mail address: hgxgene@sunm.shcnc.ac.cn (G. Hu).
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doi:10.1016/j.febslet.2008.07.009Among E2F family, E2F-4 is conservatively expressed in
normal liver tissue, while E2F-1 is not expressed in HCC tis-
sues [13]. On the other hand, microsatellite instability and
mutations of E2F-4 frequently occurred in HCC [14]. We show
here PEG10 in HCC, is promoted by a mechanism mediated
by E2F-1 and -4.2. Materials and methods
2.1. Cell culture and transfection
Human hepatocyte L02 cells [15], hepatocellular carcinoma cell
BEL-7404 and human embryonic kidney cell HEK293 (purchased
from Type Culture Collection of Chinese Academy of Sciences, Shang-
hai and ATCC, respectively) were maintained in Dulbecoos modiﬁed
Eagles medium (DMEM) containing 10% fetal bovine serum,
100 lg/ml streptomycin sulfate, and 100 lg/ml penicillin at 37 C in
5% CO2. Transient and stable transfection was performed using Lipo-
fectamine (Invitrogen) according to the manufacturers protocol.
2.2. Plasmid construction
Full-length human PEG10RF1, E2F-4, Cyclin D1 and CDK4 were
cloned into pcDNA3.1A (Invitrogen), respectively, and PEG10RF1
was also cloned into pEGFP-N1 (Clontech) to construct plasmid
expressing PEG10RF1-GFP fusion protein. The PEG10 promoter frag-
ment, corresponding to nucleotides 19,515,091–19,515,997 of GenBank
accessionNT_079595.2, were cloned into pGL3-Basic vector (Promega)
to construct the full length reporter plasmid p906, from that a series of
deletions in the promoter fragment were then constructed, respectively
(Fig. 1B). E2F binding site mutant m-p150 was constructed by point-
mutation of p150 using QuikChange II XL site-directed mutagenesis
kit (Strategene). Plasmid pcDNA-HA-E2F-1 is a kind gift from Prof.
Wu (University of Science and Technology of China, Hefei, Anhui).
2.3. Cell cycle and subG1 hypodiploid FACS analysis
After serum deprivation and re-stimulation, L02 cells were collected
at indicated time point. Cell cycle analysis was performed as described
before [16].
To test serum deprivation induced apoptosis in cells expressing GFP
fusion protein, cells were transfected with plasmids for 48 h, serum de-
prived for 48 h. Then all cells were collected, ﬁxed, permeabilizated
and analyzed as previously described [16].
2.4. Cell viability measurement
Cells were seeded in 96-well plates and then treated with serum star-
vation, cisplatin or doxorubicin (Sigma). At indicated time point cell
viability was measured by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl-2H-tetrazolium bromide] method as described previously [16].
2.5. RNA interference
Plasmids RNAi-1 and RNAi-2 which encoded shRNAs directed
against human PEG10, were constructed by cloning oligonucleotides
targeting nucleotides 1185–1203 (CACATTGAGAGAAGGCTGG)blished by Elsevier B.V. All rights reserved.
Fig. 1. Function analysis of PEG10 promoter. (A) The mRNA levels of PEG10 were tested in 14 HCC (T) and paired normal liver tissues (N), L02
cells and BEL-7404 cells by half quantitative RT-PCR. GAPDH was used as an internal control for quantiﬁcation. (B) On the left, a schematic
representation of 906 bp PEG10 promoter and its deleted variants inserted upstream of the luciferase gene in the reporter plasmid pGL3-Basic. The
numbers indicate the 5 0 and the 3 0 end of the promoter DNA inserts, in relation to the transcription start site (+1). Twenty four hours after
transfection, the luciferase activity was measured. Data are shown as mean ± S.D. of three independent experiments. (C) A putative E2F binding site
was found in the PEG10 promoter as indicated and site-directed mutagenesis of the site is also shown.
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(NM_001040152) in pSuper.gfp (OligoEngine). The empty vector
pSuper.gfp was used as control.
2.6. Luciferase reporter gene assay
To analyze PEG10 promoter function, PEG10 promoter constructs
were transfected in L02 cells. To measure responses to E2F, p150 and
mutant m-p150 were co-transfected with E2F expressing plasmid or
pcDNA3 in HEK293 cells, respectively. Plasmid pTK-RL was co-
transfected as a transfection eﬃciency control. Cells were cultured in
10% FBS for another 24 h after transfection. The luciferase activity
in cell lysates was measured by Dual luciferase assay system (Promega)
following the manufacturers protocol.
2.7. ChIP assay
A total 1 · 107 L02 cells were transfected with pcDNA-HA-E2F-1 or
not, then crosslinked with 1% formaldehyde for 15 min at room tem-
perature. ChIP assay was performed by using a ChIP Assay Kit (Up-
state) following the manufacturers protocol. Antibody against HA
(Sigma) and E2F-4 (Santa Cruz) was used. For covering E2F binding
site in PEG10 promoter primers were designed as follows:
Forward: 5 0-CGGAGCACGCTGGGATTTG-3 0
Reverse: 5 0-AGGCGCGGTCTCCACTG-3 0
2.8. Quantitative real-time RT-PCR assay and half quantitative
RT-PCR
Total RNA extraction from cells and tissues and reverse transcrip-
tion were performed as described previously [17]. To measure mRNA
level, real-time PCR assays were performed on a DNA Engine Opticon2 (MJ Research) using the DyNAmo SYBR Green qPCR kit (FINN-
ZYMES). A threshold cycle value for each mRNA was determined
using the Opticon Monitor software (version 2.02). All data were nor-
malized to the GAPDH mRNA level and expressed as mRNA relative
change. The mRNA levels of E2F-1, E2F-4 and PEG10 in tissues were
detected by half quantiﬁed PCR assays and then measured using
TotalLab (Non-linear Dynamics). Expression changes between tumor
and normal were calculated as Log2 (Tumor/Normal). Primers used in
PCR were designed as follows:
PEG10-forward: 5 0-CCCCGGGCGCTGGTGTTG-3 0
PEG10-reverse: 5 0-AGCGGGGCCGGGGAGTTTC-3 0
BCL-xL-forward: 5 0-CTGTGCGTGGAAAGCGTAGA-3 0
BCL-xL-reverse: 5 0-TGCTGCATTGTTCCCATAGAG-3 0
GAPDH-forward: 5 0-GGGGAGCCAAAAGGGTCATCATCT-3 0
GAPDH-reverse: 5 0-GAGGGGCCATCCACAGTCTTCT-3 0
E2F-1-forward: 5 0-CCGCCATCCAGGAAAAGGT-3 0
E2F-1-reverse: 5 0-GCCCTCAAGGACGTTGGTG-30
E2F-4-forward: 5 0-TGTTTGGCCTACGTCACTCAT-3 0
E2F-4-reverse: 5 0-ACACTCTTCAGGTGAATCTGGTA-3 0
2.9. Clinical samples
Clinical HCC samples at stages II and III by pathological exami-
nation were collected from Zhongshan Hospital immediately after
surgery. The paired normal liver samples were 3 cm away from the
edge of HCC lesions from the same patients. The 14 HCC patients
(male/female, 9/5) were aged 31–71. Access to human tissues com-
plied with both Chinese laws and the guidelines of the Ethics Com-
mittee.
Fig. 2. PEG10 is a direct target of E2F. (A) ChIP assay showed E2F-1 and E2F-4 binded to the PEG10 promoter region containing the putative site.
GAPDH was used as a negative control. (B) A 150 bp fragment containing E2F-like binding element of the PEG10 promoter has E2F-response
activity in the luciferase report assay which is abrogated by a point-mutation in the element. Details were described in Section 2. (C) Eﬀects of the
E2F-1, -4 and Cyclin D/CDK4 complex overexpression on the PEG10 mRNA expression in L02 cells. Forty eight hours after transfection of
indicated plasmids, mRNA level of PEG10 gene was measured by quantitative real-time PCR, normalized mRNA level of GAPDH housekeeping
gene. Cells transfected with control plasmid pcDNA3 were deﬁned as 1. (D) Eﬀects of TGFb stimulation on the PEG10 mRNA expression in BEL-
7404 cells. Cells were treated with 2 ng/ml TGF-b for 48 h. The mRNA level of PEG10 gene was measured as above. Cells without stimulation were
deﬁned as 1. Data are shown as mean ± S.D. of three independent experiments. *P < 0.01. (E) Expression of E2F in HCC clinical samples.
Expression patterns of E2F-1 and E2F-4 in 14 pairs of clinical samples. Samples were divided into two groups, positive and negative, according to the
expression of PEG10 in tumor. Each column represented a pair of HCC samples. Graduated colour patterns correspond to the degrees of expression
changes (Tumor vs. Normal).
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3.1. PEG10 is up-regulated in HCC
We examined the mRNA expression levels of PEG10 in
clinic HCC samples and paired normal liver tissues. Ten out
of 14 samples showed elevated mRNA levels of PEG10 in tu-
mors compared to paired normal tissues (Fig. 1A). Consis-
tently, the mRNA level of PEG10 was low in normal hepatic
cell L02 and high in hepatocellular carcinoma cell BEL-7404
(Fig. 1A). These data veriﬁed previous reports that PEG10
was up-regulated in HCC [6].
3.2. Conﬁrmation of the E2F regulatory element inPEG10
promoter
In order to investigate transcriptional regulation of PEG10
expression, the promoter fragment between 906 and +1 of
PEG10 gene was subcloned into luciferase reporter vector. A
series of reporter plasmids containing various deletions in the
promoter fragment were also constructed. All these reporters
were transiently transfected into L02 cells, to quantify pro-
moter activities. The luciferase activity of empty vector was
used as the reference for normalizing the activities of the other
constructs (Fig. 1B). Deletion analyses of PEG10 promoter re-
vealed that the p150 exhibited a highest level of activity. Sim-
ilar high levels of activity were observed for the other plasmids
except pD906 that lacked the region 96/+1 of PEG10 pro-
moter and exhibited much lower activity (about 10% of activ-
ity of p150) (Fig. 1B). These data indicated that a key
regulatory element was located in the region between 96and +1. Then we investigated putative transcriptional factor-
binding sites in 96/+1 region using the MatInspector data-
base. As shown in Fig. 1C, within the region of 50/+1, there
was one putative E2F binding site. Thus, E2F was probably a
key transcriptional factor responsible for PEG10 regulation.
3.3. E2F-1 and E2F-4 bind to the promoter and regulate the
transcription of PEG10
Among E2F family, E2F-4 was expressed in normal liver
while E2F-1 was expressed in HCC. Thus, we investigated
whether PEG10 was regulated by them. The results of CHIP
showed that both exogenous E2F-1 and endogenous E2F-4
could bind to PEG10 promoter (Fig. 2A). To determine
whether the putative binding site is essential for E2F to regu-
late the transcription of PEG10, luciferase plasmids with wild
type or mutated E2F binding sequence were constructed (Fig.
1C). Luciferase report assay showed that both exogenous E2F-
1 and -4 up-regulated the promoter activity of the wild type
p150 but not mutant m-p150 (Fig. 2B). Interestingly, E2F-1
even repressed that of m-p150. Consistently, the overexpres-
sion of E2F-1 and -4 in L02 cells could up-regulate the expres-
sion of PEG10 at mRNA level (Fig. 2C). These ﬁndings
indicated that both E2F-1 and -4 could positively regulate
the transcriptional expression of PEG10 by directly binding
to its promoter.
PEG10 is a target of E2F, so it is reasonable to expect PEG10
can be regulated by E2F/Rb pathway. Cyclin D/CDK4
complex, in this pathway, can phosphorylate pocket proteins
and release E2F [18], and TGF-b can repress expression
Fig. 3. PEG10 expression varies during cell cycle. L02 cells were seeded, serum-starved (S) and then re-treated with 10% serum (R). (A) Cell cycle was
analyzed at indicated time point. Black: G1 phase; white: S phase; grey: G2/M phase. (B) At indicated time point the mRNA level of PEG10 was
measured by quantitative real-time PCR.
2796 C. Wang et al. / FEBS Letters 582 (2008) 2793–2798of E2F target gene by keeping Rb dephosphorylated and
inducing the formation of E2F-4/p107 or E2F-4/Rb complexes
[19]. We found that overexpression of Cyclin D/CDK4
complex, as well as E2F-1 and -4, caused elevated mRNA level
of PEG10 in L02 cells (Fig. 2C). On the other hand, mRNA
level of PEG10 was signiﬁcantly decreased when we treated
BEL-7404 cells with TGF-b (Fig. 2D). These results also sup-
ported indirectly that PEG10 was a target of E2F.
In support to our results, previous microarray studies
showed that PEG10 (KIAA1051) was up-regulated on overex-
pression of E2F-1, -2 or -3 in osteosarcoma cells U2OS [20], as
well as on knockdown of Rb1 in non-small lung carcinoma
cells H1299 [21]. And cDNA array data from Tsou et al. sug-
gested that in HCC clinical samples the expression proﬁle of
PEG10 was similar to that of many E2F target genes, such
as CDK4, CDC45, CDC20 [5].
3.4. Expression of E2F in HCC tissues
As described above, PEG10 was found to be a target of E2F
in cultured cells. We then investigated whether there is a corre-
lation between PEG10 and E2F expression in HCC. We exam-
ined the mRNA expression levels of E2F-1 and E2F-4 in clinic
HCC samples. Coincident with results in cells, E2F-1 expres-
sion was positive correlated to PEG10 expression (Fig. 2E),
suggesting the overexpression of PEG10 in HCC was caused
by upregulated E2F-1. But E2F-4 expression seemed negative
correlated unexpectedly (Fig. 2E). It has been considered that
E2F-4 is properly expressed in normal liver and represses the
expression of target genes in association with pocket proteins,
p107 and p130. When E2F-4 is decreased, the repression will
be abrogated and target genes can be transcribed [22]. Mean-
while, E2F-4 has trans-activating capability and also can trans-
criptionally stimulate E2F target gene promoters [23], which
could explain our results on overexpression experiments of
E2F-4 in cells. However, the ‘‘loss of repression’’ mechanism
may be predominant in vivo as implied by the result from clin-
ical samples.
3.5. Expression of PEG10 varies during cell cycle
Since a variety of E2F target genes participate in cell cycle
control, especially in G1/S transition, we wonder whether
PEG10 is involved in this process. L02 cells were arrested inG1 phase by serum deprivation and re-entered cell cycle after
serum re-stimulation (Fig. 3A). It was observed that the
mRNA level of PEG10 was increased following serum depriva-
tion and was decreased after serum re-stimulation (Fig. 3B).
However, ectopic expression of PEG10 in synchronized L02
cells or knocking down of PEG10 in BEL-7404 cells barely af-
fected the transition from G1 phase to S phase (data not
shown). These results suggested that PEG10 may be expressed
during G1 phase rather than during G2 phase. But PEG10
seemed not to play a role in G1/S transition.
3.6. PEG10 protects hepatic cells from apoptosis induced by
serum deprivation and chemotherapeutic drugs
Because E2F/Rb pathway is involved in not only cell cycle
control but also cell fate decision including apoptosis, we
then investigate the function of PEG10 in apoptosis. Ectopic
expression of PEG10 rather than GFP protein in L02 cells
markedly reduced cell apoptosis induced by serum depriva-
tion (Fig. 4A). In reverse, the cell apoptosis induced by serum
deprivation would signiﬁcantly increase if the expression of
PEG10 was knocked down with RNAi in BEL-7404 cell
(Fig. 4B and C). Meanwhile, more survival cells after serum
deprivation were observed in PEG10 stable transfected L02
cells compared to the cells treated with empty plasmid (Fig.
4D). Similar results were obtained when cells were treated
with cisplatin or doxorubicin (Fig. 4F). Together, these re-
sults suggested that the existence of PEG10 could protect he-
patic cells from apoptosis. In addition, we found that the
mRNA level of BCL-xL, an important anti-apoptosis pro-
tein, was elevated in PEG10 stable transfected cells (Fig.
4E), probably underlying the mechanism for apoptosis resis-
tance of PEG10.
Previous reports indicated that PEG10 has a positive role in
cell proliferation [7,24]. Data in this study suggested that
PEG10 is also involved in resistance to apoptosis induced by
serum starvation and chemotherapeutic drugs. These data
indicated that PEG10 may have a role in development of
HCC. Two candidate pathways, inhibition of SIAH function
and inhibition of TGF-b have been reported to explain how
PEG10 performs anti-apoptosis activity. Our data suggested
that induction of BCL-xL by PEG10 may also have contribu-
tion in this process.
Fig. 4. PEG10 protects hepatic cell lines against apoptosis. L02 cells (A) and BEL-7404 cells (C) were transfected with indicated plasmids and
deprived of serum, and then subG1 hypodiploid FACS analysis of GFP positive cells were performed. Arrows indicated the increased apoptosis cells.
(B) Knocking down of PEG10 by RNAi plasmids. Forty eight hours after transfection of indicated plasmids, the mRNA level of PEG10 gene was
measured. Cells transfected with control plasmid pSuper.gfp were deﬁned as 1. (D) Growth rates of PEG10 and pcDNA3 stable transfected L02 cells
in serum deprivated medium. (E) The mRNA levels of BCL-xL in the above cells were measured by quantitative real-time PCR. D0 and D5 indicated
0 and 5 days after serum deprivation. (F) PEG10 and pcDNA3 stable transfected and wild type L02 cells were treated with 10 mM cisplatin or 2 mM
doxorubicin for 24 and 48 h, the viability of cells were counted by MTT assay. Data are shown as mean ± S.D. of three independent experiments.
*P < 0.01.
C. Wang et al. / FEBS Letters 582 (2008) 2793–2798 2797Epigenetic phenomena, including de novo methylation and
loss of imprinting, have been well documented in preneoplastic
and malignant tissues [25], but how classic genetic pathways
contribute to the dysregulated expression of imprinted genes
is less concerned. E2F/Rb pathway is a classic genetic pathway
involved in a variety of human cancers [12], and genetic study
in HCC has shown that microsatellite instability and muta-
tions of E2F-4 occur commonly in HCC [14]. Here we reportedthat the imprinted gene PEG10 is a target of E2F, providing a
link between genetics and epigenetics in HCC.
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